Mastopon-Treat

Progesterone, the active ingredient in Mastopon-Treat, is a progestogen presented as a topical formulation for topical use. It is employed in hormone therapy to support menstrual cycle regulation and to alleviate menopausal symptoms in women.

GNH USA supplies Mastopon-Treat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. With a focus on regulatory compliance, GNH USA ensures product integrity throughout the supply chain, meeting the needs of diverse healthcare markets.

Progesterone in Mastopon-Treat acts on the endocrine system to provide progestational support in several hormone‑related conditions. - Menopause: alleviates vasomotor symptoms and helps maintain endometrial stability when combined with estrogen. - Luteal phase support: supports the uterine lining in assisted reproductive cycles to improve implantation potential. - Premenstrual syndrome: reduces mood swings, breast tenderness, and bloating associated with the luteal phase.

Topical progesterone may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Skin irritation at the application site: redness, itching or mild rash. - Localized swelling: mild edema where the product is applied. - Headache: transient mild headache reported by some users. - Nausea: occasional mild nausea unrelated to systemic absorption.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling of face, lips or throat requiring immediate medical attention. - Thromboembolic events: rare clot formation especially in patients with pre‑existing risk factors. - Hormone‑dependent tumor progression: potential acceleration of existing breast or endometrial cancers.

When using Mastopon-Treat, several precautions should be observed to ensure safety and product efficacy. - Assess medical history: verify absence of active hormone‑dependent malignancies before initiating therapy. - Monitor for clotting disorders: avoid use in patients with known thromboembolic disease. - Evaluate pregnancy status: progesterone therapy is generally contraindicated during pregnancy unless specifically prescribed. - Review concomitant medications: consider potential interactions with anticoagulants or hormonal agents. - Follow application guidelines: apply a thin layer to clean, dry skin and avoid occlusion. - Store below 25°C: keep in the original container, protect from moisture and light.

Progesterone can influence the activity of several drugs, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): progesterone may enhance anticoagulant effect, increasing bleeding risk. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce progesterone levels, compromising therapeutic effect.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: concurrent use may alter cycle regulation; monitor for breakthrough bleeding. - Antifungal azoles (e.g., ketoconazole): can increase progesterone concentrations, potentially leading to side effects. - Antidepressants (SSRIs): may modestly affect hormone metabolism; observe for mood changes.